This project will develop a multi-targeting high-affinity mAb to treat MM, which is primarily targeted to the commercial market. By 2025 the global therapeutic mAb market is expected to generate revenue of $300 billion. Most mAbs for cancer therapy, target only one receptor/protein on the cancer cell surface, in which acquired resistance to these mAbs frequently occurs via downregulation of the antibody target from the cancer cell surface, leading to reduced clinical utility/efficacy overtime. By targeting multiple receptors with high affinity this novel mAb will exhibit enhanced clinical efficacy over existing mAbs. It is anticipated that the optimised/final candidate mAb will be deployed in various settings, including clinical and industrial settings. The key project outcomes will enable the research and development of a novel mAb and assessment of effectiveness against clinically relevant MM samples, so that GCU/Antibody Company/UoS can market this mAb, and identify requirements for further mAb innovation. The long-term outcomes of this research will positively impact clinical outcomes, such as survival and quality of life in MM patients
|Short title||Generation of a Novel Therapeutic Antibody for Myeloma|
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.